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A novel approach for the synthesis of chiral tetrasubstituted pyrrolidines has been developed. The
rearrangement of isoxazolidines into tetrahydro-1,3-oxazines using reactive organic bromides is
herein described for the first time. The subsequent opening reaction of these tetrahydro-1,3-oxazines
with nucleophiles probes the usefulness of the method for the synthesis of biologically active
compounds.
Introduction
Nitrones and sulfones are two of the most important functional
groups in organic chemistry due to their versatility.1 Nitrones
undergo several synthetically useful reactions such as 1,3-dipolar
cycloadditions and nucleophilic additions, which make them
ideal tools for the construction of highly functionalized nitrogen
heterocycles.2 Especially important are the cyclic nitrones, as
they have been applied to the synthesis of many biologically
active natural products.3 The excellent properties of the sulfone
group as well as its being easily removable, have made it
increasingly important in synthetic chemistry, for example in the
synthesis of demanding and sophisticated complex molecules
such as peptide-based inhibitors.4 Although there is very
extensive literature dedicated to the study of cyclic nitrones5
and vinyl sulfones,6 studies of the reactivity of both together are
scarce.7 Recently, we studied the reactivity of several cyclic
nitrones with phenylvinylsulfone (Scheme 1).8
This study started with the aim of obtaining pyrrolidine-based
organocatalysts with a phenylsulfone group. In order to
synthesize the required organocatalysts it was necessary to open
the isoxazolidine ring. This step has usually been achieved by
cleavage of the N–O bond, mainly by reduction,9 oxidation10
with m-CPBA or alkylation of the nitrogen atom followed by
treatment with base.11
Results and discussion
We initially focused our attention on the ring opening reaction of
compounds 2a–c and 3a–c (Scheme 2), as they are the
straightforward precursors for the organocatalysts.
Treatment of isoxazolidines 2a,2b and 3a,3b with Mo(CO)6,
for the reductive cleavage of the N–O bond9c (Table 1, entries 1,
3, 5 and 7) gave the expected products, 4a,4b and 5a,5b,
respectively. Surprisingly, when compounds 2c and 3c were
submitted to these conditions, not only were the corresponding
pyrrolidines 4c and 5c obtained, but two other rearranged
products, identified as the corresponding bicyclic tetrahydro-1,3-
oxazines 10 and 11 respectively (entries 9 and 11), were obtained.
As we were aware of the importance of this rearrangement, we
focused our attention on the alkylation conditions, in order to
see if this rearrangement takes place with alkylating agents
(Table 1). When isoxazolidines 2a–c and 3a–c were submitted to
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treatment with benzyl bromide it was observed that pyrrolidines
with no substituents in the 3 or 4 positions (entries 2 and 4)
undergo alkylation of the nitrogen atom with neither ring
opening nor rearrangement. Pyrrolidines 2b and 3b, protected
with benzyl groups (entries 6 and 8), gave products resulting
from alkylation, followed by ring opening (8b and 9b respec-
tively) in low yield by transformation in the work up or
chromatography. To our delight, for compounds with an
acetonide group (entries 10 and 12) the rearrangement was the
only reaction, producing tetrahydro-1,3-oxazines 12a and 13a
in moderate and good yields respectively. The stereochemistry
of the rearranged compounds was easily established by the
observation of no coupling between the H-5 and H-4 hydrogens
in the 1H NMR spectra and corroborated by X-ray analysis for
compound 13a (Fig. 1).12
This rearrangement could be understood as a 1,3-hydride shift
from the C–H in the a-position with regard to the tertiary amine
(tert-amino effect) to the oxygen of the isoxazolidine (Pathway A
in Scheme 3). The structural rigidity of the tricyclic derivatives 2c
and 3c could be responsible for their unique reactivity, forcing
the topology required in the transition state. Therefore, this
could represent a nice example of a 1,3-hydride shift triggered
reaction cascade involving ring opening–ring closure sequences
which, to the best of our knowledge, are quite uncommon.
Related intramolecular hydride shift–ring closure transforma-
tions are known, including some recent advances through
catalytic approaches.13 It could also be considered a deprotona-
tion–ring opening followed by the cyclization step (Pathway B in
Scheme 3). More synthetic studies to better understand the
mechanism are being conducted.
This kind of behaviour of the isoxazolidine moiety for these
kinds of compounds has rarely been observed. The related
formation of oxazines from isoxazolidines has been observed by
Uccella and co-workers through alkylation of the isoxazolidines
to give isoxazolidinium salts, followed by treatment with a
base.14
The novelty of the reactions reported herein rests in their
occurrence under thermal conditions with no reagent added,
which would further support a 1,3-hydride shift mechanism.
Table 1 Ring opening reaction of isoxazolidines 2a–c and 3a–c
Entry Compound Conditionsa Product (% yield)b
1 2a A 4a(35)
2 2a B 6a (24)
3 3a A 5a (35)
4 3a B 7a (55)
5 2b A 4b (20)
6 2b B 8b (10)
7 3b A 5b (—)
8 3b B 9b (10)
9 2c A 4c (50), 10 (50)
10 2c B 12a (46)
11 3c A 5c (20), 11 (53)
12 3c B 13a (67)
a Conditions A: Mo(CO)6, H2O–MeCN, reflux, 24 h; conditions B:
BnBr, CHCl3, reflux, 20 h.
b Yield of isolated product.
Fig. 1 X-ray crystal structure of compound 13a. Displacement ellip-
soids are drawn at the 30% probability level. Hydrogen atoms are shown
as spheres of arbitrary radius.
Scheme 2 Ring opening reaction of isoxazolidines 2a–c and 3a–c
(details of reaction conditions A or B are given in Table 1).
Scheme 3 Suggested mechanisms for the synthesis of tetrahydro-1,3-
oxazines.





















































Formation of tetrahydro-1,3-oxazines from tertiary amines
bearing an OH group able to trap the intermediate iminium
ion is a well established process occurring usually by oxidation or
under photochemical conditions.15 The particular structure of
adducts 2c and 3c seems to suggest kinetic lability of the C–H a
to N for stereoelectronic reasons, according to similar observa-
tions reported for the oxidation of the parent hydroxylamines to
the corresponding nitrones.16
Having obtained bicyclic aminals 12 and 13, and taking into
account the importance of nitrones such as 1c, which has been
used in the synthesis of many natural and biologically active
compounds,3b,3c we decided to explore the scope of the reaction
using different alkylating agents (Table 2). The rearrangement of
isoxazolidines 2c and 3c to the bicyclic system only works with
very effective alkylating agents such as allylic or benzylic species,
and in higher yields with bromides than with chlorides (entries 5–
8 and 9, 10). When geranyl bromide was employed, no reaction
with 2c occurred due to the steric hinderence of the sulfonyl
group; the yield was low with 3c (entry 11). Moreover, no
reaction occurred in any case with either saturated alkyl
bromides or acyl compounds.
To demonstrate the importance of this reaction, we decided to
open the bicyclic system with different nucleophiles as has been
done with other aminals, in particular by Bosch and Amat.17
Compounds 12a and 13a were chosen as starting materials.
First of all, 12a and 13a were treated with methylmagnesium
bromide. When the reaction was performed using 1, 3 or even 5
equivalents of the Grignard reagent, ring opening either did not
occur or only occurred in poor yield. The desired products (14a
and 15a) were formed in high yield only when using at least 10
equivalents of the nucleophile (Table 3, entries 1 and 2).
Moreover, lithium nucleophiles resulted in quite poor yields or
no reaction, irrespective of the number of equivalents used
(entries 3 and 4). Other Grignard reagents led to the opening of
the aminal in high yields when 10 equivalents were used (entries
5–10). In this manner, pyrrolidines with four chiral centers were
obtained in high yield in a simple way.
It can be observed that the configuration of the sulfone group
does not influence the stereochemistry of the incoming nucleo-
phile; in all cases, the same a-Nu were obtained independently of
the starting material 12a or 13a. The stereochemistry of the ring
opened product was established by analysis of the NMR
experiments (bidimensional and NOE, see ESI{) and confirmed
by transformation of 14a and 15a into pyrrolidine 16 by
treatment with Na(Hg) amalgam as shown in Scheme 4. Since
the stereochemistry of 16 is known,18 it could be established that
the nucleophile had entered through the a side. The stereo-
chemistry was also corroborated by transformation of com-
pound 15h in the same manner to form meso diolefin 17.
In order to further extend the applicability of this methodol-
ogy, compound 16, which had previously been transformed by
Palmer and Ja¨ger into biologically active pyrrolidines,18 was
submitted to hydroboration and oxidation affording pyrrolidine
Table 2 Isoxazolidine to oxazine rearrangementa
Entry S. M. RX Product Yield (%)
1 2c 12a 46
2 2c 12b 60
3 2c b 30
4 2c 12d 25
5 3c 13a 67
6 3c 13a 20
7 3c 13b 74
8 3c 13b —
9 3c 13c 25
10 3c 13c —
11 3c 13d 30
12 3c 13e 80
13 3c 13f 35
14 3c 13g 20
a Isoxazolidine (1 mmol) in CHCl3 (0.06 M); RX (1 mmol), 60 uC for
20 h. b In this case, only the alkylation product was isolated in 30%
yield.
Table 3 Opening of aminalsa
Entry S. M. Nucleophile Product Yield (%)
1 12a MeMgBr 14a Nu = Me 85
2 13a MeMgBr 15a Nu = Me 98
3 13a MeLi 15a Nu = Me 40
4 13a n-BuLi 15b Nu = Bu —
5 13a EtMgBr 15c Nu = Et 98
6 13a PhMgBr 15d Nu = Ph 70
7 13a AllylMgBr 15e Nu = Allyl 85
8 13a 2-NaphCH2MgBr 15f Nu = 2-NaphCH2- 80
9 13a c-hexCH2MgBr 15g Nu = c-hexCH2- 90
10 13a VinylMgBr 15h Nu = Vinyl 54
a 12a or 13a (1 mmol) , Et2O (0.08 M); NuMgBr (10 mmol) or NuLi
(10 mmol), 260 uC for 2 h.





















































18, the C-5 epimer of which has been previously transformed
into a fucosidase inhibitor by Defoin et al..19
As depicted in Scheme 4, both compounds 14a and 15a led to the
same olefin 16, which increased the yield of the final product (18).
Conclusions
A new method for the synthesis of chiral pyrrolidines is
described. This approach is based on the rearrangement of
chiral isoxazolidines into tetrahydro-1,3-oxazines by treatment
with reactive organic bromides. Opening of the obtained
tetrahydro-1,3-oxazines with different nucleophiles affords the
corresponding chiral pyrrolidines in a diastereoselective manner.
These compounds can be used for diversity oriented synthesis of
biologically active compounds.
Experimental section
N–O cleavage of isoxazolidines using Mo(CO)6: standard
procedure
To a stirred solution of isoxazolidine (1 mmol) in 1 mL of H2O
and 15 mL of MeCN was added 0.7 mmol of Mo(CO)6 and the
mixture was heated at reflux. The solution was stirred for 24 h
then concentrated in vacuo. The resulting crude residue was
purified by flash chromatography (silica gel, hexane–EtOAc
1 : 1) to obtain rearranged compound.
(19R*,2R*)-2-(1-Phenylsulfonyl-2-hydroxyethyl)pyrrolidine 4a.
IR (film): 3299, 29589, 2924, 1447, 1304, 1144, 691 cm21; 1H
NMR (200 MHz, CDCl3) d 7.99–7.58 (5H, m, HAr), 4.11–4.04
(1H, m, HA-29), 3.89–3.84 (1H, m, HB-29), 3.50–47 (1H, m,
H-19), 3.00–2.93 (3H, m, H-2 and H-5), 2.10–1.74 (4H, m, H-3
and H-4); 13C NMR (50 MHz, CDCl3) d 139.0, 134.2, 129.5,
128.7, 67.3, 59.1, 56.1, 45.8, 31.3, 25.5; HRMS (EI) calcd for
C12H17NO3S (M + H)
+ 256.0929; found 256.1017.
(19R,2R,4S,5S)-2-(1-Phenylsulfonyl-2-hydroxyethyl)-4,5-bis
(benzyloxy)pyrrolidine 4b. [a]20D 222.0 (c 0.4, MeOH); IR (film):
3431, 2922, 2851, 1628, 1449, 1148, 1086, 698 cm21; 1H NMR
(200 MHz, CDCl3) d 7.87–7.22 (15H, m, HAr), 4.56–4.34 (4H, m,
CH2–Bn), 4.34 (1H, d, J = 2.2 Hz, H-3), 4.03–3.87 (3H, m, H-2
and H-29), 3.88 (1H, t, J = 5.8 Hz, H-4), 3.57–3.43 (1H, m, H-19),
3.89–3.84 (1H, m, HB-29), 3.50–47 (1H, m, H-19), 3.25 (1H, dd, J =
5.6 and 12.0 Hz, HB-5), 3.07 (1H, dd, J = 1.8 and 12.0 Hz, HA-5),
2.07 (2H, bs, NH and OH); 13C NMR (50 MHz, CDCl3) d 138.4,
137.9, 137.8, 134.1, 129.5, 128.8, 128.7, 128.5, 128.2, 128.1, 128.0,
127.9, 85.5, 82.5, 71.9, 71.6, 61.9, 60.2, 50.4; HRMS (EI) calcd for
C26H30NO5S (M + H)
+ 468.1815; found 468.1819.
(19R,2R,3S,4R)-2-(1-Phenylsulfonyl-2-hydroxyethyl)-3,4-iso-
propylidenedioxypyrrolidine 4c. [a]20D = +2.1 (c = 2.5, CHCl3); IR
(film): 3481, 3334, 2987, 2909, 2840, 1434, 1144, 1042 cm21; 1H
NMR (400 MHz, CDCl3) d 7.91 (2H, d, J = 8.2 Hz, Hortho),
7.69 (1H, t, J = 7.4 Hz, Hpara), 7.59 (2H, d, J = 7.4 Hz,
Hmeta), 5.15 (1H, d, J = 5.6 Hz, H-3), 4.75 (1H, t, J = 4.7 Hz,
H-4), 3.90 (1H, dd, J = 3.4 and 11.8 Hz, HA-29), 3.80 (1H, dd, J
= 7.7 and 13.2 Hz, HB-29), 3.69 (1H, d, J = 10.0 Hz, H-2), 3.15–
3.06 (1H, m, H-19), 3.08 (1H, d, J = 13.6 Hz, HB-5), 2.97 (1H,
dd, J = 13.6 Hz, HA-5), 1.45 (3H, s, Me-acetonide), 1.33 (3H, s,
Me-acetonide); 13C NMR (100 MHz, CDCl3) d 137.5, 134.2,
129.3, 128.9, 111.4, 84.8, 81.0, 65.4, 63.4, 61.6, 51.6, 26.3, 24.1;




IR (film): 3343, 3065, 2961, 2874, 1304, 1144, 1049, 760, 691,
565 cm21; 1H NMR (200 MHz, CDCl3) d 7.99–7.58 (5H, m,
HAr), 4.13–3.95 (1H, m, HA-29), 3.87–3.81 (1H, m, HB-29), 3.50–
3.47 (1H, m, H-19), 3.02–2.85 (3H, m, H-2 and H-5), 2.13–1.74
(4H, m, H-3 and H-4); 13C NMR (50 MHz, CDCl3) d 139.0,
134.3, 129.6, 128.7, 68.2, 59.7, 56.2, 46.5, 31.3, 25.4; HRMS (EI)
calcd for C12H17NO3S (M + H)
+ 256.0929; found 256.1017.
(19S,2R,3S,4R)-2-(1-Phenylsulfonyl-2-hydroxyethyl)-3,4-iso-
propylidenedioxypyrrolidine 5c. [a]20D 232.0 (c 1.5, CHCl3); IR
(film): 3501, 3326, 2983, 2913, 1446, 1283 cm21; 1H NMR
(400 MHz, CDCl3) d 7.94 (2H, d, J = 7.4 Hz, Hortho), 7.65 (1H,
t, J = 7.4 Hz, Hpara), 7.58 (2H, d, J = 7.4 Hz, Hmeta), 4.75–4.70
(2H, m, H-3 and H-4), 4.06 (1H, dd, J = 4.9 and 13.2 Hz, HB-29),
3.99 (1H, dd, J = 3.5 and 13.2 Hz, HA-29), 3.52 (1H, dd, J = 2.5
and 8.4 Hz, H-2), 3.19–3.18 (1H, m, H-19), 3.02 (1H, dd, J = 4.6
and 11.8 Hz, HA-5), 2.97 (1H, d, J = 11.8 Hz, HB-5), 2.82 (1H, s,
N–H), 1.44 (3H, s, Me-acetonide), 1.30 (3H, s, Me acetonide);
13C NMR (100 MHz, CDCl3) d 138.7, 133.4, 129.1, 128.9, 112.7,
83.6, 80.8, 67.9, 62.3, 59.4, 51.8, 26.8, 24.6; HRMS (EI) calcd for
C15H22NO5S (M + H)
+ 328.1213; found 328.1202.
(1R,4R,5R,6S,7S)-4-Phenylsulfonyl-6,7-isopropylidendioxy-2-
oxa-8-azabicyclo[3.2.1]octane 10. [a]20D 22.7 (c 0.7, CHCl3); IR
(film): 2982, 2934, 2882, 1301, 1148, 733 cm21; 1H NMR
(200 MHz, CDCl3) d 7.94 (2H, d, J = 8.0 Hz, Hortho), 7.70–7.56
(3H, m, Hmeta and Hpara), 4.86 (1H, s, H-1), 4.75 (1H, dd, J =
1.2 and 5.4 Hz, H-6), 4.55, 4.48 (2H, m, H-7 and HB-3), 3.87 (1H,
dd, J = 5.8 and 14.2 Hz, HA-3), 3.77 (1H, bs, H-5), 2.73 (1H, dd,
J = 3.0 and 5.8 Hz, H-4), 1.45 (3H, s, Me-acetonide), 1.31 (3H, s,
Me acetonide); 13C NMR (50 MHz, CDCl3) d 137.5, 134.6,
129.8, 128.9, 112.9, 88.8, 81.9, 78.7, 59.1, 57.9, 56.5, 26.1, 24.9;
HRMS (EI) calcd for C15H20NO5S (M + H)
+ 326.1056; found
326.1067.
Scheme 4 a. Na(Hg) 5%, MeOH, r.t., 2 h, 100%; b. 9-BBN, THF,
NaBO3, r.t., 30%; c. Na(Hg) 5%, MeOH, r.t., 2 h, 100%.






















































oxa-8-azabicyclo[3.2.1]octane 11. [a]20D = +20.0 (c = 0.9, CHCl3);
IR (film): 3412, 3338, 2974, 2929, 1373, 1140, 1033 cm21; 1H
NMR (400 MHz, CDCl3) d 7.82 (2H, d, J = 8.0 Hz, Hortho),
7.70 (1H, t, J = 7.6 Hz, Hpara), 7.60 (2H, d, J = 7.6 Hz, Hmeta),
5.32 (1H, d, J = 5.4 Hz, H-6), 4.77 (1H, s, H-1), 4.72 (1H, d, J =
5.4 Hz, H-7), 4.01 (1H, dd, J = 5.8 and 11.8 Hz, HB-3), 3.87 (1H,
t, J = 11.8 Hz, HA-3), 3.77 (1H, sa, H-5), 3.50 (1H, ddd, J = 2.6,
5.8 and 8.4 Hz, H-4), 1.45 (3H, s, Me-acetonide), 1.38 (3H, s, Me
acetonide); 13C NMR (100 MHz, CDCl3) d 137.7, 134.4, 129.6,
128.2, 111.7, 88.8, 81.8, 78.7, 61.3, 59.6, 57.9, 25.7, 24.4; HRMS
(EI) calcd for C15H20NO5S (M + H)
+ 326.1056; found 326.1068.
Alkylation of heterocycles: standard procedure
To a stirred solution of isoxazolidine (1 mmol) in CHCl3
(0.06 M) was added dropwise RBr (1 mmol) and the solution
heated at 60 uC. The solution was stirred at 60 uC for 20 h. Then
it was quenched with saturated aqueous solution of NH4Cl and
the product was extracted with DCM (3615 mL). The combined
organic layers were washed with brine, dried (Na2SO4), filtered,
and concentrated in vacuo. The resulting crude residue was
purified by flash chromatography (silica gel, hexane–EtOAc
8 : 2) to obtain the rearranged compound.
(3R*,3aR*)-N-Benzyl-3-phenylsulfonylhexahydropyrrolo[1,2-
b]-isoxazole 6a. IR (film): 3314, 2928, 2872, 1447, 1306, 1049,
916, 691, 600 cm21; 1H NMR (200 MHz, CDCl3) d 7.89–7.15
(10H, m, HAr), 4.23–3.96 (1H, m, HA-2), 3.90–3.88 (1H, m, HB-
2 and H-3), 3.60–3.24 (3H, m, H-3a, HA-6 and HA–CH2Bn),
3.03–2.95 (1H, m, HB-6), 2.95 (1H, d, J = 12.3 Hz, HB–CH2Bn),
2.33–2.05 (2H, m, H-4), 1.95–1.87 (1H, m, HA-5), 1.78-1.13 (1H,
m, HB-5);
13C NMR (50 MHz, CDCl3) d 138.7, 134.3, 129.5,
129.4, 129.2, 128.9, 128.2, 127.9, 63.3, 62.1, 59.4, 58.6, 53.7,




isoxazole 7a. IR (film): 3397, 2993, 2882, 1449, 1152, 723, 602
cm21; 1H NMR (200 MHz, CDCl3) d 8.08–7.26 (10H, m, HAr),
5.90 (1H, d, J = 12.8 Hz, HB–CH2Bn), 5.45–5.42 (1H, m, H-3a),
5.29–4.99 (3H, m, H-2 and HA–CH2Bn), 4.72–4.64 (1H, m, H-3),
4.39–4.28 (1H, m, HB-6), 3.66–3.62 (1H, m, HA-6), 3.46–3.38
(1H, m, HB-4), 2.98–2.94 (1H, m, HA-5), 2.27–2.11 (2H, m, HA-4
and HB-5);
13C NMR (50 MHz, CDCl3) d 136.6, 135.6, 132.7,
131.1, 130.4, 129.3, 129.0, 127.8, 79.3, 71.2, 10.8, 66.7, 66.0, 31.7,




4,5-bis(benzyloxy)pyrrolidine 8b. [a]20D 235.7 (c 0.4, MeOH); IR
(film): 3422, 2955, 2922, 2851, 1701, 1609, 1497, 1364, 1146,
1086, 802, 698 cm21; 1H NMR (200 MHz, CDCl3) d 7.85–7.12
(20H, m, HAr), 4.46–4.39 (6H, m, H-3, H-4 and CH2–Bn), 4.05
(1H, dd, J = 8.8 and 11.8 Hz, HA-29), 3.99 (1H, dd, J = 3.8 and
11.8 Hz, HB-29), 3.87–3.79(1H, m, H-2), 3.85 (1H, d, J = 12.8 Hz,
HA–NCH2), 3.68–3.58 (1H, m, H-19), 3.58 (1H, d, J = 12.8 Hz,
HB–NCH2), 3.05 (1H, d, J = 11.4 Hz, HA-5), 2.70 (1H, dd, J =
4.4 and 11.4 Hz, HB-5), 1.50 (1H, bs, OH);
13C NMR (50 MHz,
CDCl3) d 138.7, 138.5, 138.2, 137.6, 134.1, 129.6, 129.1, 128.7,
128.1, 127.9, 127.8, 127.6, 87.7, 81.8, 77.3, 71.5, 71.3, 66.9, 61.9,




4,5-bis(benzyloxy)pyrrolidine 9b. [a]20D 215.7 (c 0.2, MeOH); IR
(film): 3404, 3059, 2916, 1603, 1560, 1306, 1084, 689, 573 cm21;
1H NMR (200 MHz, CDCl3) d 7.91–7.12 (10H, m, HAr), 4.78–
4.41 (6H, m, H-3, H-4 and CH2–Bn), 4.26 (1H, dd, J = 8.0 and
11.8 Hz, HA-29), 4.12 (1H, dd, J = 3.8 and 11.8 Hz, HB-29), 4.07–
3.87(1H, m, H-2), 3.82 (1H, d, J = 12.8 Hz, HA–NCH2), 3.49–
3.45 (1H, m, H-19), 3.30 (1H, d, J = 12.8 Hz, HB–NCH2), 3.05
(1H, d, J = 10.2 Hz, HA-5), 2.46 (1H, dd, J = 3.6 and 10.2 Hz,
HB-5) 1.56 (1H, bs, OH); HRMS (EI) calcd for C33H36NO5S
(M + H)+ 558.2308; found 558.2296.
(1R,4R,5R,6S,7S)-8-Benzyl-4-phenylsulfonyl-6,7-isopropyliden-
dioxy-2-oxa-8-azabicyclo[3.2.1]octane 12a. [a]20D 231.7 (c 0.6,
CHCl3); IR (film): 3391, 3060, 2970, 2921, 1446, 1385, 1152
cm21; 1H NMR (200 MHz, CDCl3) d 7.85–7.30 (10H, m, HAr),
4.71 (1H, s, H-1), 4.62 (1H, d, J = 5.0 Hz, H-7), 4.52 (1H, d, J =
5.0 Hz, H-6), 4.38 (1H, d, J = 12.0 Hz, HA–CH2Bn), 4.26–4.23
(1H, m, HA-3), 4.20 (1H, d, J = 12.0 Hz, HB–CH2Bn), 4.13 (1H,
s, H-5), 3.85–3.75 (1H, m, HB-3), 3.10 (1H, t, J = 6.2 Hz, H-4),
1.52 (3H, s, Me-acetonide), 1.29 (3H, s, Me-acetonide); 13C
NMR (50 MHz, CDCl3) d 138.9, 138.5, 134.4, 129.8, 128.7,
128.4, 127.3, 113.3, 90.1, 84.6, 83.1, 61.8, 59.6, 58.4, 52.6, 25.9,




dendioxy-2-oxa-8-azabicyclo[3.2.1]octane 12b. [a]20D 231.7 (c 0.6,
CHCl3); IR (film): 3069, 2982, 2932, 2860, 1447, 1306, 1209,
1450, 1072, 731, 606 cm21; 1H NMR (200 MHz, CDCl3) d 7.89
(2H, d, J = 8.2 Hz, Hortho), 7.70–7.52 (3H, m, Hpara and
Hmeta), 5.75–5.58 (1H, m, H-29), 5.31 (1H, dd, J = 1.8 and
13.6 Hz, HA-39), 5.14 (1H, dd, J = 1.8 and 13.6 Hz, HB-39), 4.70
(1H, s, H-1), 4.62 (1H, d, J = 5.4 Hz, H-6), 4.51 (1H, d, J =
5.4 Hz, H-7), 4.20–4.09 (2H, m, 2H-3), 4.05 (1H, s, H-5), 3.80–
3.55 (2H, m, H-4 and HA-19), 3.07–3.01 (1H, m, HB-19), 1.48
(3H, s, Me-acetonide), 1.26 (3H, s, Me-acetonide); 13C NMR
(50 MHz, CDCl3) d 138.7, 135.3, 134.3, 129.7, 128.8, 117.3,
113.4, 90.3, 84.7, 83.5, 62.3, 59.8, 58.4, 51.9, 26.1, 25.0; HRMS




denedioxyhexahydropyrrolo[1,2-b]isoxazole 12c. [a]20D = +5.5 (c =
0.2, CHCl3); IR (film): 3275, 2955, 2924, 2851, 1260, 1145, 758,
689, 584 cm21; 1H NMR (200 MHz, CDCl3) d 7.90 (2H, d, J =
7.8 Hz, Hortho), 7.66–7.53 (3H, m, Hpara and Hmeta), 5.08 (1H,
dd, J = 3.0 and 6.6 Hz, H-4), 4.76–4.72 (1H, m, H-5), 4.12 (1H,
dd, J = 5.4 and 12.4 Hz, HB-2), 3.98 (1H, dd, J = 6.6 and
12.4 Hz, HA-2), 3.57–3.31 (1H, m, H-3a, H-3, 2H-19), 3.08 (1H,
dd, J = 3.0 and 13.2 Hz, HB-5), 2.98 (1H, dd, J = 5.6 and
13.2 Hz, HA-5), 2.18 (1H, t, J = 2.4 Hz, H-39), 1.47 (3H, s, Me-
acetonide), 1.31 (3H, s, Me-acetonide); 13C NMR (50 MHz,
CDCl3) d 139.1, 134.2, 129.3, 129.2, 112.4, 84.2, 79.4, 77.8, 73.9,





















































67.3, 65.0, 60.6, 56.7, 43.4, 27.4, 24.9; HRMS (EI) calcd for
C18H23NO5NaS (M + Na) 388.1189; found 388.1195.
(1R,4R,5R,6S,7S)-8-Methylcrotonate-4-phenylsulfonyl-6,7-iso-
propylidendioxy-2-oxa-8-azabicyclo[3.2.1]octane 12d. [a]20D 223.6
(c 1.4, CHCl3); IR (film): 3429, 2980, 2851, 1719, 1447, 1152,
978, 691 cm21; 1H NMR (400 MHz, CDCl3) d 7.88 (2H, d, J =
8.0 Hz, Hortho), 7.67 (1H, m, Hpara), 7.57 (H, m, Hmeta), 6.80
(1H, dt, J = 4.8 and 16.0 Hz, H-39), 6.15 (1H, dt, J = 1.8 and
16.0 Hz, H-29), 4.67 (1H, s, H-1), 4.63 (1H, d, J = 5.4 Hz, H-7),
4.51 (1H, d, J = 5.4 Hz, H-6), 4.14 (1H, dd, J = 5.4 and 12.6 Hz,
HB-3), 4.10 (1H, s, H-5), 4.03 (1H, ddd, J = 1.9, 4.8 and 6.4 Hz,
HB-19), 3.88 (1H, ddd, J = 1.9, 4.8 and 6.4 Hz, HA-19), 3.76 (1H,
dd, J = 6.5 and 12.6 Hz, HA-3), 3.04–3.01 (1H, m, H-4), 3.75
(3H, s, CO2CH3), 1.49 (3H, s, Me-acetonide), 1.26 (3H, s, Me-
acetonide); 13C NMR (50 MHz, CDCl3) d 167.2, 145.6, 138.6,
134.4, 129.8, 128.7, 121.9, 113.4, 90.0, 84.3, 83.0, 61.7, 60.0, 58.5,
51.7, 49.4, 25.9, 24.8; HRMS (EI) calcd for C20H26NO7S
(M + H)+ 424.1424.; found 424.1434.
(1R,4S,5R,6S,7S)-8-Benzyl-4-phenylsulfonyl-6,7-isopropyliden-
dioxy-2-oxa-8-azabicyclo[3.2.1]octane 13a. [a]20D 228.3 (c 0.7,
CHCl3); IR (film): 3387, 2978, 2864, 1589, 1397, 1140 cm
21; 1H
NMR (200 MHz, CDCl3) d 7.84–7.52 (10H, m, HAr), 5.34 (1H,
d, J = 5.8 Hz, H-6), 4.72 (1H, d, J = 5.8 Hz, H-7), 4.50 (1H, s,
H-1), 4.14–3.97 (3H, m, CH2Bn and 1H-3), 3.84 (1H, t, J =
14.8 Hz, H-3), 3.73 (1H, ddd, J = 2.6, 6.2 and 8.8 Hz, H-4), 3.56
(1H, s, H-5), 1.52 (3H, s, Me-acetonide), 1.37 (3H, s, Me
acetonide); 13C NMR (50 MHz, CDCl3) d 138.1, 137.3, 134.4,
129.8, 128.7, 128.3, 127.5, 112.5, 89.6, 81.4, 77.4, 59.9, 59.8, 54.1,
48.3, 26.4, 25.4; HRMS (EI) calcd for C22H25NO5NaS (M + Na)
438.1345; found 438.1349.
(1R,4S,5R,6S,7S)-4-Phenylsulfonyl-8-propenyl-6,7-isopropyli-
dendioxy-2-oxa-8-azabicyclo[3.2.1]octane 13b. [a]20D 213.7 (c 0.6,
CHCl3); IR (film): 3067, 2982, 2936, 1310, 1246, 1101, 903, 866,
731, 604 cm21; 1H NMR (200 MHz, CDCl3) d 7.85 (2H, d, J =
8.0 Hz, Hortho), 7.72–7.52 (3H, m, Hpara and Hmeta), 5.71–5.63
(1H, m, H-29), 5.33 (1H, d, J = 5.4 Hz, H-6), 5.20 (1H, dd, J =
1.8 and 7.2 Hz, HA-39), 5.02 (1H, dd, J = 1.8 and 7.2 Hz, HB-39),
4.70 (1H, d, J = 5.4 Hz, H-7), 4.51 (1H, s, H-1), 4.02–3.87 (2H,
m, 2H-3), 3.60 (1H, s, H-5), 3.59–3.42 (2H, m, H-4 and HA-19),
3.29–3.19 (1H, m, HB-19), 1.45 (3H, s, Me-acetonide), 1.36 (3H,
s, Me-acetonide).); 13C NMR (50 MHz, CDCl3) d 138.1, 134.5,
134.3, 129.9, 128.4, 117.6, 112.6, 89.5, 81.5, 77.9, 59.9, 59.8, 53.9,




dendioxy-2-oxa-8-azabicyclo[3.2.1]octane 13c. [a]20D = +8.4 (c =
1.6, CHCl3); IR (film): 3275, 2957, 2924, 2853, 1381, 1319, 885,
727, 604 cm21; 1H NMR (200 MHz, CDCl3) d 7.88 (2H, d, J =
8.0 Hz, Hortho), 7.70–7.57 (3H, m, Hpara and Hmeta), 5.36 (1H,
d, J = 6.0 Hz, H-6), 4.72 (1H, d, J = 6.0 Hz, H-7), 4.56 (1H, s,
H-1), 4.02 (1H, dd, J = 1.8 and 11.6 Hz, HB-3), 3.91 (1H, d, J =
11.6 Hz, HA-3), 3.81 (1H, s, H-5), 3.66 (1H, ddd, J = 1.8, 6.6 and
9.6 Hz, H-4), 2.05 (1H, t, J = 2.6 Hz, H-39), 1.46 (3H, s, Me-
acetonide), 1.37 (3H, s, Me-acetonide); 13C NMR (50 MHz,
CDCl3) d 139.0, 134.5, 129.9, 128.5, 112.9, 89.6, 81.6, 78.2, 77.9,
59.8, 59.7, 53.8, 34.3, 26.4, 25.7; HRMS (EI) calcd for
C18H22NO5S (M + H)
+ 364.1210; found 364.1211.
(1R,4S,5R,6S,7S)-8-Geranyl-4-phenylsulfonyl-6,7-isopropyli-
dendioxy-2-oxa-8-azabicyclo[3.2.1]octane 13d. [a]20D 27.3 (c 0.5,
CHCl3); IR (film): 2963, 2926, 2855, 1458, 1375, 1153, 885,
604 cm21; 1H NMR (200 MHz, CDCl3) d 7.87 (2H, d, J = 8.0
Hz, Hortho), 7.69–7.55 (3H, m, Hpara and Hmeta), 5.32 (1H, d,
J = 5.8 Hz, H-6), 5.09–5.02 (2H, m, H-299 and H-699), 4.68 (1H,
d, J = 5.8 Hz, H-7), 4.48 (1H, s, H-1), 4.02–3.87 (2H, m, H-3),
3.64–3.59 (2H, m, H-4 and H-5), 3.36 (1H, dd, J = 6.2 and 12.8
Hz, HA-199), 3.25 (1H, dd, J = 7.2 and 12.8 Hz, HB-199), 2.03–
1.28 (13H, m, geranyl), 1.45 (3H, s, Me-acetonide), 1.36 (3H, s,
Me-acetonide); 13C NMR (50 MHz, CDCl3) d 139.6, 138.3,
134.4, 131.9, 129.8, 128.4, 120.2, 112.7, 89.6, 81.6, 78.4, 59.8,
59.7, 41.7, 39.7, 34.5, 26.6, 26.4, 25.9, 25.7, 17.9, 16.8; HRMS
(EI) calcd for C25H36NO5S (M + H)
+ 462.2308; found 462.2318.
(1R,4S,5R,6S,7S)-4-Phenylsulfonyl-8-((E)-4-bromobut-2-en-1-
yl)-6,7-isopropylidendioxy-2-oxa-8-azabicyclo[3.2.1]octane 13e.
[a]20D 28.0 (c 0.3, CHCl3); IR (film): 3348, 2984, 2928, 2853,
1447, 1373, 1207, 725, 604 cm21; 1H NMR (200 MHz, CDCl3) d
7.82 (2H, d, J = 8.0 Hz, Hortho), 7.72–7.57 (3H, m, Hpara and
Hmeta), 5.97–5.93 (2H, m, H-39), 5.90–5.57 (1H, m, H-29), 5.33
(1H, d, J = 6.0 Hz, H-6), 4.84 (1H, s, H-1), 4.69 (1H, d, J = 6.0
Hz, H-7), 3.97–3.82 (3H, m, H-4 and 2H-3), 3.58 (1H, s, H-5),
3.57–3.20 (4H, m, 2H-19 and 2H-49), 1.44 (3H, s, Me-acetonide),
1.21 (3H, s, Me-acetonide). 13C NMR (50 MHz, CDCl3) d 138.1,
134.6, 131.3, 129.4, 128.4, 128.2, 112.6, 89.5, 81.4, 78.3, 60.1,
59.8, 54.1, 45.3, 32.1, 26.3, 25.5; HRMS (EI) calcd for
C19H26NO5SBr (M + H)
+ 458.0631; found 458.0644.
(1R,4S,5R,6S,7S)-8-Methylcrotonate-4-phenylsulfonyl-6,7-iso-
propylidendioxy-2-oxa-8-azabicyclo[3.2.1]octane 13f. [a]20D 213.1
(c 0.9, CHCl3); IR (film): 3412, 2988, 2951, 1719, 1375, 1319,
1308, 1086, 723 cm21; 1H NMR (400 MHz, CDCl3) d 7.82 (2H,
d, J = 8.0 Hz, Hortho), 7.64 (1H, m, Hpara), 7.55 (H, m, Hmeta),
6.74 (1H, dt, J = 1.8 and 15.0 Hz, H-39), 6.04 (1H, dt, J = 5.0 and
15.0 Hz, H-29), 5.29 (1H, d, J = 5.8 Hz, H-6), 4.66 (1H, d, J = 5.8
Hz, H-7), 4.45 (1H, s, H-1), 3.91–3.88 (2H, m, H-3), 3.66 (3H, s,
CO2CH3), 3.63 (1H, ddd, J = 1.8, 5.0 and 16.0 Hz, HB-19), 3.62
(1H, s, H-5), 3.59–3.54 (1H, m, H-4), 3.35 (1H, ddd, J = 1.8, 5.0
and 16.0 Hz, HA-19), 1.44 (3H, s, Me-acetonide), 1.21 (3H, s, Me-
acetonide); 13C NMR (50 MHz, CDCl3) d 166.7, 144.2, 137.9,
134.6, 129.9, 128.3, 122.7, 112.6, 89.6, 81.3, 78.3, 60.4, 59.8, 54.3,
51.7, 44.7, 26.2, 25.3; HRMS (EI) calcd for C20H25NO7NaS (M
+ Na) 446.1243; found 446.1249.
(1R,4S,5R,6S,7S)-8-Methylacetate-4-phenylsulfonyl-6,7-iso-
propylidendioxy-2-oxa-8-azabicyclo[3.2.1]octane 13g. [a]20D 211.0
(c 0.5, CHCl3); IR (film): 2980, 2955, 2918, 2872, 2849, 1751,
1431, 1379, 1287, 1086, 885, 735 cm21; 1H NMR (200 MHz,
CDCl3) d 7.86 (2H, d, J = 7.8 Hz, Hortho), 7.71–7.61 (3H, m,
Hpara and Hmeta), 5.35 (1H, d, J = 6.0 Hz, H-6), 4.72 (1H, d, J
= 6.0 Hz, H-7), 4.63 (1H, s, H-1), 3.91–3.79 (2H, m, H-3), 3.79
(1H, s, H-5), 3.75 (1H, d, J = 16.4 Hz, HA-19), 3.65 (3H, s,
CO2CH3), 3.56–3.45 (1H, m, H-4), 3.41 (1H, d, J = 16.4 Hz, HB-
19), 1.48 (3H, s, Me-acetonide), 1.37 (3H, s, Me-acetonide); 13C
NMR (50 MHz, CDCl3) d 170.1, 138.1, 134.6, 129.9, 128.4,





















































113.2, 90.6, 81.6, 78.6, 61.5, 59.8, 54.8, 52.2, 46.6, 26.4, 25.9;
HRMS (EI) calcd for C18H24NO7S (M + H)
+ 398.1268; found
398.1261.
Addition of organometallic reagents: standard procedure
To a stirred solution of rearranged compound (1 mmol) in Et2O
(0.08 M) was added dropwise RMgBr or RLi (10 mmol) at
260 uC. The solution was stirred at 260 uC for 2 h. Then the
mixture was allowed to warm slowly to room temperature. It was
quenched with a saturated aqueous solution of NH4Cl and the
product was extracted with DCM (3615 mL). The combined
organic layers were washed with brine, dried (Na2SO4), filtered,
and concentrated in vacuo. The resulting crude residue was
purified by flash chromatography (silica gel, hexane–EtOAc
1 : 1) to obtain the pyrrolidine product.
(19R,2R,3S,4R,5R)-1-Benzyl-5-methyl-2-(1-phenylsulfonyl-2-
hydroxyethyl)-3,4-isopropylidenedioxypyrrolidine 14a. [a]20D 24.3
(c 0.4, CHCl3); IR (film): 2959, 2920, 2851, 1144, 1051, 800, 584
cm21; 1H NMR (200 MHz, CDCl3) d 7.92–7.25 (10H, m, HAr),
5.04 (1H, dd, J = 2.6 and 6.0 Hz, H-3), 4.35 (1H, dd, J = 3.2 and
6.0 Hz, H-4), 4.01 (1H, dd, J = 4.4 and 12.0 Hz, HA-29), 3.89
(1H, d, J = 13.2 Hz, HA-CH2Bn), 3.66–3.56 (2H, m, H-2 and HB-
29), 3.64 (1H, d, J = 13.2 Hz, HB- CH2Bn), 3.42–3.36 (1H, m,
H-19), 3.12 (1H, dq, J = 3.2 and 7.0 Hz, H-5), 1.45 (3H, s, Me-
acetonide), 1.30 (3H, s, Me-acetonide), 1.20 (3H, d, J = 7.0 Hz,
Me–C-5); 13C NMR (50 MHz, CDCl3) d 138.0, 135.7, 134.2,
129.8, 129.4, 128.8, 128.7, 127.8, 112.5, 86.4, 84.2, 69.0, 66.9,
64.1, 60.0, 59.4, 27.6, 25.3, 19.8; HRMS (EI) calcd for
C23H30NO5NaS (M + Na) 454.1658; found 454.1640.
(19S,2R,3S,4R,5R)-1-Benzyl-5-methyl-2-(1-phenylsulfonyl-2-
hydroxyethyl)-3,4-isopropylidenedioxypyrrolidine 15a. [a]20D =
+5.8 (c = 0.7, CHCl3); IR (film): 3474, 2986, 2965, 2934, 1449,
1381, 1308, 1043, 691 cm21; 1H NMR (400 MHz, CDCl3) d 7.94–
7.55 (10H, m, HAr), 4.76 (1H, d, J = 6.0 Hz, H-3), 4.09 (1H, t, J
= 6.5 Hz, H-4), 4.06 (1H, ddd, J = 1.0, 4.7 and 11.6 Hz, HA-29),
3.96 (1H, dd, J = 7.5 and 11.6 Hz, HB-29), 3.82 (1H, d, J = 13.6
Hz, HA–CH2Bn), 3.59 (1H, s, H-2), 3.49 (1H, d, J = 13.6 Hz,
HB–CH2Bn), 3.03–2.99 (1H, m, H-19), 2.70–2.67 (1H, m, H-5),
1.41 (3H, s, Me-acetonide), 1.29 (3H, s, Me-acetonide), 1.20 (3H,
d, J = 6.0 Hz, Me–C-5); 13C NMR (100 MHz, CDCl3) d 138.0,
135.7, 133.9, 129.5, 129.2, 128.8, 128.6, 127.7, 112.5, 84.6, 78.6,
65.7, 63.5, 63.3, 58.4, 56.3, 27.9, 25.8, 17.6; HRMS (EI) calcd for
C23H30NO5S (M + H)
+ 432.1815; found 432.1824.
(19S,2R,3S,4R,5R)-1-Benzyl-5-ethyl-2-(1-phenylsulfonyl-2-
hydroxyethyl)-3,4-isopropylidenedioxypyrrolidine 15c. [a]20D =
+4.4 (c = 0.9, CHCl3); IR (film): 3412, 2963, 2932, 2876, 1449,
1308, 1065, 733, 689 cm21; 1H NMR (200 MHz, CDCl3) d 7.79–
6.98 (10H, m, Ar), 4.79 (1H, dd, J = 1.8 and 6.2 Hz, H-3), 4.26
(1H, t, J = 6.2 Hz, H-4), 4.09–3.95 (2H, m, H-29), 3.87 (1H, d, J
= 13.6 Hz, HA–CH2Bn), 3.58 (1H, bs, H-2), 3.50 (1H, d, J = 13.6
Hz, HB–CH2Bn), 2.95–2.92 (1H, m, H-19), 2.69–2.60 (1H, m,
H-5), 1.77–1.67 (2H, m, –CH2–C-5), 1.41 (3H, s, Me-acetonide),
1.30 (3H, s, Me-acetonide), 0.97 (3H, t, J = 7.8 Hz, CH3–
CH3CH2–C-5).
13C NMR (50 MHz, CDCl3) d 138.3, 136.3,
134.2, 129.7, 129.4, 128.9, 128.0, 112.6, 83.3, 79.1, 69.2, 66.1,
63.8, 58.5, 57.3, 23.5, 26.1, 25.3, 9.4; HRMS (EI) calcd for
C24H31NO5NaS (M + Na)
+ 468.1815; found 468.1805.
(19S,2R,3S,4R,5R)-1-Benzyl-2-(1-phenylsulfonyl-2-hydro-
xyethyl)-5-phenyl-3,4-isopropylidenedioxypyrrolidine 15d. [a]20D =
+6.2 (c = 0.3, CHCl3); IR (film): 3497, 3063, 3030, 2988, 2934,
2872, 2857, 1493, 1308, 1217, 1030, 596 cm21; 1H NMR
(400 MHz, CDCl3) d 7.86–6.81 (15H, m, Ar), 4.81 (1H, dd, J
= 1.6 and 6.0 Hz, H-3), 4.31 (1H, t, J = 6.7 Hz, H-4), 4.25 (1H,
dd, J = 5.6 and 11.9 Hz, HA-29), 4.14 (1H, dd, J = 5.6 and 11.9
Hz, HB-29), 3.73 (1H, d, J = 13.7 Hz, HA–CH2Bn), 3.60–3.58
(2H, m, H-2 and H-5), 3.34 (1H, d, J = 13.7 Hz, HB–CH2Bn),
3.11–3.07 (1H, m, H-19), 1.50 (3H, s, Me-acetonide), 1.28 (3H, s,
Me-acetonide); 13C NMR (100 MHz, CDCl3) d 139.2, 138.0,
135.1, 134.1, 129.6, 129.2, 128.5, 128.1, 127.7, 127.3, 112.7, 85.3,
78.9, 72.1, 64.3, 58.0, 55.4, 27.9, 25.8; HRMS (EI) calcd for
C28H31NO5NaS (M + Na)
+ 516.1833; found 516.1805.
(19S,2R,3S,4R,5R)-1-Benzyl-2-(1-phenylsulfonyl-2-hydro-
xyethyl)-5-propenyl-3,4-isopropylidenedioxypyrrolidine 15e. [a]20D =
+4.3 (c = 0.5, CHCl3); IR (film): 3503, 2982, 2916, 2848, 1449,
1150, 1070, 737, 590 cm21; 1H NMR (200 MHz, CDCl3) d 7.91–
7.24 (10H, m, Ar), 5.90–5.76 (1H, m, H-299), 5.20–5.03 (2H, m,
H-399), 4.78 (1H, dd, J = 2.0 and 6.2 Hz, H-3), 4.31 (1H, t, J =
6.2 Hz, H-4), 4.09–3.98 (2H, m, H-29), 3.91 (1H, d, J = 13.2 Hz,
HA–CH2Bn), 3.58 (1H, s, H-2), 3.56 (1H, d, J = 13.2 Hz, HB–
CH2Bn), 3.09–2.95 (1H, m, H-19), 2.48–2.16 (3H, m, H-5, H-199),
1.42 (3H, s, Me-acetonide), 1.29 (3H, s, Me-acetonide); 13C NMR
(50 MHz, CDCl3) d 138.8, 138.3, 136.2, 135.7, 134.3, 129.7, 129.4,
129.3, 128.5, 127.3, 118.4, 112.7, 82.4, 79.0, 67.6, 65.4, 64.1, 58.4,
57.1, 36.2, 28.1, 26.0; HRMS (EI) calcd for C25H32NO5S
(M + H)+ 458.1995; found 458.1978.
(19S,2R,3S,4R,5R)-1-Benzyl-5-naphthalenylmethyl-2-(1-phe-
nylsulfonyl-2-hydroxyethyl)-3,4-isopropylidenedioxypyrrolidine
15f. [a]20D = +30.4 (c = 2.6, CHCl3); IR (film): 3449, 2986, 2932,
1449, 1306, 1148, 752, 689 cm21; 1H NMR (200 MHz, CDCl3) d
7.81–7.09 (17H, m, Ar), 4.78 (1H, dd, J = 1.8 and 5.4 Hz, H-3),
4.38 (1H, t, J = 5.4 Hz, H-4), 3.99–3.86 (2H, m, H-29), 3.80 (1H,
d, J = 13.2 Hz, HA–CH2Bn), 3.77 (1H, bs, H-2), 3.50 (1H, d, J =
13.2 Hz, HB–CH2Bn), 3.20–3.26 (2H, m, H-199), 3.09–3.04 (1H,
m, H-19), 2.85–2.80 (1H, m, H-5), 1.36 (3H, s, Me-acetonide),
1.26 (3H, s, Me-acetonide); 13C NMR (50 MHz, CDCl3) d 138.3,
136.5, 135.4, 133.7, 129.8, 129.4, 129.1, 128.3, 127.9, 127.7, 126.4,
125.7, 112.5, 83.3, 79.4, 69.4, 66.5, 64.5, 58.5, 39.5, 28.2, 26.1;





[a]20D = +7.8 (c = 0.4, CHCl3); IR (film): 3462, 2986, 2851,
1449, 1308, 1063, 754, 592 cm21; 1H NMR (200 MHz, CDCl3) d
7.77–7.02 (10H, m, Ar), 4.82 (1H, dd, J = 1.8 and 6.0 Hz, H-3),
4.23 (1H, t, J = 6.0 Hz, H-4), 4.05–3.92 (2H, m, H-29), 3.85 (1H,
d, J = 13.2 Hz, HA–CH2Bn), 3.53 (1H, bs, H-2), 3.48 (1H, d, J =
13.2 Hz, HB–CH2Bn), 3.46 (2H, d, J = 6.6 Hz, H-199), 2.95–2.79
(2H, m, H-5 and H-19), 1.86–1.53 (11H, m, cyclohexyl), 1.31 (3H,
s, Me-acetonide), 1.41 (3H, s, Me-acetonide); 13C NMR
(50 MHz, CDCl3) d 138.3, 136.3, 134.2, 129.9, 129.4, 129.1,





















































128.1, 112.5, 84.9, 79.4, 69.1, 66.0, 65.4, 63.5, 58.7, 57.4, 41.9,
40.7, 34.9, 34.3, 32.9, 28.1, 26.8, 26.4, 26.1; HRMS (EI) calcd for
C29H39NO5NaS (M + Na)
+ 536.2440; found 536.2441.
(19S,2R,3S,4R,5R)-1-Benzyl-2-(1-phenylsulfonyl-2-hydro-
xyethyl)-5-vinyl-3,4-isopropylidenedioxypyrrolidine 15h. [a]20D =
+40.0 (c = 0.3, CHCl3); IR (film): 2984, 2920, 2849, 1449,
1215, 1070, 690 cm21; 1H NMR (200 MHz, CDCl3) d 7.97–6.95
(10H, m, Ar), 5.79–5.61 (1H, m, H-199), 5.40–5.29 (2H, m, H-299),
4.79 (1H, dd, J = 1.2 and 5.6 Hz, H-3), 4.26 (1H, t, J = 7.0 Hz,
H-4), 4.07 (1H, dd, J = 4.2 and 11.8 Hz, HA-29), 3.93 (1H, dd,
J = 5.8 and 11.8 Hz, HB-29), 3.89 (1H, d, J = 13.2 Hz, HA–
CH2Bn), 3.60 (1H, s, H-2), 3.35 (1H, d, J = 13.2 Hz, HB–
CH2Bn), 3.08 (1H, t, J = 7.8 Hz, H-199), 2.93–2.95 (1H, m, H-19),
1.46 (3H, s, Me-acetonide), 1.30 (3H, s, Me-acetonide); 13C
NMR (50 MHz, CDCl3) d 138.2, 137.3, 135.8, 134.4, 129.9,
129.5, 129.2, 128.8, 128.1, 120.1 112.8, 83.2, 79.3, 72.4 64.9, 63.7,
58.5, 56.1, 28.2, 26.1; HRMS (EI) calcd for C25H32NO5NaS (M
+ Na), 466.1658; found 466.1660.
(2S,3S,4R,5R)-1-Benzyl-3,4-isopropylidenedioxy-5-methyl-2-
vinylpyrrolidine 16
a) To a solution of pyrrolidine 15a (40 mg, 0.09 mmol) in MeOH
(1.5 mL) was added 128 mg (0.28 mmol) of 5% Na (Hg)
amalgam at r.t. The mixture was stirred for 2 h at this
temperature under an argon atmosphere. Next, it was filtered
to remove the Hg residue and diluted with DCM (30 mL). The
mixture was washed with brine, dried (Na2SO4), filtered, and
concentrated. The resulting crude residue was purified by flash
chromatography (silica gel, n-hexane–EtOAc 6 : 4) to obtain 16
(25 mg, 100%). [a]20D 25.0 (c 0.5, CH2Cl2); IR (film): 2980, 2965,
2930, 1449, 1246, 1148, 1070, 866 cm21; 1H NMR (200 MHz,
CDCl3) d 7.31–7.21 (5H, m, HAr), 5.84–5.66 (1H, m, H-19),
5.39–5.20 (2H, m, H-29), 4.29 (1H, dd, J = 5.0 and 6.8 Hz, H-3),
4.16 (1H, dd, J = 4.8 and 6.8 Hz, H-4), 3.84 (1H, d, J = 14.6 Hz,
HA–CH2Bn), 3.49 (1H, d, J = 14.6 Hz, HB–CH2Bn), 3.09 (1H,
dd, J = 5.0 and 8.4 Hz, H-2), 2.70–2.64 (1H, m, H-5), 1.43 (3H, s,
Me-acetonide), 1.29 (3H, s, Me-acetonide), 1.22 (3H, d, J = 5.6
Hz, Me–C-5); 13C NMR (50 MHz, CDCl3) d 138.8, 137.6, 129.5,
128.2, 127.1, 118.9, 113.5, 85.4, 83.5, 72.9, 63.9, 53.4, 27.5, 25.6,
18.5; HRMS (EI) calcd for C17H24NO2 (M + H)
+ 274.1801;
found 274.1800.
b) To a solution of pyrrolidine 14a (10 mg, 0.02 mmol) in
MeOH (1 mL) was added 48 mg (0.06 mmol) of 5% Na (Hg)
amalgam at r.t. The mixture was stirred for 2 h at this
temperature under an argon atmosphere. Next, it was filtered
to eliminate the Hg residue and diluted with DCM (30 mL). The
mixture was washed with brine, dried (Na2SO4), filtered, and
concentrated. The resulting crude residue was purified by flash




To a solution of pyrrolidine 15h (24 mg, 0.06 mmol) in MeOH
(1 mL) was added 75 mg (0.16 mmol) of 5% Na (Hg) amalgam at
r.t. The mixture was stirred for 2 h at this temperature under an
argon atmosphere. Next, it was filtered to remove the Hg residue
and diluted with DCM (30 mL). The mixture was washed with
brine, dried (Na2SO4), filtered, and concentrated. The resulting
crude residue was purified by flash chromatography (silica gel,
n-hexane–EtOAc 6 : 4) to obtain 17 (17 mg, 100%). IR (film):
2982, 2924, 1375, 1267, 1072, 922, 866, 704 cm21; 1H NMR
(200 MHz, CDCl3) d 7.26–7.21 (5H, m, HAr), 5.82–5.84 (2H, m,
H-19), 5.38 (2H, d, J = 1.8 Hz, HA-29), 5.20 (2H, dd, J = 5.0 and
6.8 Hz, HB-29), 4.30 (2H, dd, J = 1.2 and 3.0 Hz, H-3 and H-4),
3.70 (2H, bs, CH2Bn), 3.12 (2H, dd, J = 1.8 and 7.8 Hz, H-2 and
H-5), 1.42 (3H, s, Me-acetonide), 1.27 (3H, s, Me-acetonide); 13C
NMR (50 MHz, CDCl3) d 138.5, 136.5, 130.1, 128.1, 127.1,
118.9, 113.7, 83.7, 77.3, 71.7, 52.6, 27.4, 25.6; HRMS (EI) calcd
for C18H24NO2 (M + H)
+ 286.1803; found 286.1801.
(2S,3S,4R,5R)-1-Benzyl-3,4-isopropylidenedioxy-5-
methylpyrrolidine-2-ethanol 18
9-BBN (1.8 ml, 0.9 mmol) was added to a solution of
vinylpyrrolidine 16 (50 mg, 0.18 mmol) in THF (1.50 mL) at
0 uC. The reaction mixture was stirred at r.t. for 4 h. A saturated
aqueous solution of NaBO3 was added and the resulting mixture
was stirred at r.t. for 18 h. The reaction product was then
extracted with DCM (3615 mL). The combined organic layers
were washed with brine, dried (Na2SO4), filtered, and concen-
trated. The resulting crude residue was purified by flash
chromatography (silica gel, n-hexane–EtOAc 6 : 4) to obtain
18 (15 mg, 30%). [a]20D 212.8 (c 0.8, CH3Cl); IR (film): 3397,
2980, 2932, 2866, 1452, 1341, 1028, 733, 702 cm21; 1H NMR
(200 MHz, CDCl3) d 7.33–7.17 (5H, m, HAr), 4.29 (1H, dd, J =
5.0 and 6.8 Hz, H-3), 4.16 (1H, dd, J = 4.6 and 6.8 Hz, H-4),
4.05–3.99 (1H, m, HA-29), 3.84 (1H, d, J = 14.3 Hz, HA–CH2Bn),
3.54–3.40 (1H, m, HB-29), 3.49 (1H, d, J = 14.3 Hz, HB–CH2Bn),
3.12–3.05 (1H, m, H-2), 2.70–2.64 (1H, m, H-5), 1.95–1.85 (1H,
m, HA-19), 1.83–1.75 (1H, m, HB-19), 1.44 (3H, s, Me-acetonide),
1.29 (3H, s, Me-acetonide), 1.17 (3H, d, J = 5.6 Hz, Me–C-5);
13C NMR (50 MHz, CDCl3) d 135.2, 132.3, 130.4, 128.6, 113.2,
83.5, 81.2, 72.7, 68.663.5, 54.4, 27.6, 24.3, 17.6; HRMS (EI) calcd
for C17H26NO3 (M + H)
+ 292.1907; found 292.1911.
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